NewAmsterdam Pharma (NASDAQ:NAMS) Given "Sell (D-)" Rating at Weiss Ratings

Key Points

• NewAmsterdam Pharma's stock received a "sell (D-)" rating from Weiss Ratings, indicating a negative outlook from analysts.
• The company's stock has been rated mainly as a "Moderate Buy" by eight analysts, with a current average target price of $42.00.
• In a recent earnings report, NewAmsterdam Pharma surpassed expectations with a reported EPS of ($0.15), compared to a consensus estimate of ($0.52).

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report)'s stock had its "sell (d-)" rating reiterated by research analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

NAMS has been the subject of several other reports. Royal Bank Of Canada boosted their price target on NewAmsterdam Pharma from $38.00 to $39.00 and gave the company an "outperform" rating in a research note on Thursday, August 7th. Stifel Nicolaus assumed coverage on NewAmsterdam Pharma in a research note on Tuesday, June 10th. They issued a "buy" rating and a $44.00 price target for the company. Needham & Company LLC restated a "buy" rating and issued a $40.00 price target on shares of NewAmsterdam Pharma in a research note on Thursday, June 12th. Wall Street Zen upgraded NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a research note on Saturday, July 5th. Finally, Wells Fargo & Company initiated coverage on NewAmsterdam Pharma in a report on Monday, August 25th. They issued an "overweight" rating and a $45.00 price objective for the company. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $42.00.

NewAmsterdam Pharma Trading Up 2.0%

Shares of NASDAQ NAMS opened at $32.86 on Wednesday. NewAmsterdam Pharma has a 12 month low of $14.06 and a 12 month high of $34.62. The stock has a 50 day moving average of $25.83 and a 200-day moving average of $21.48. The company has a market capitalization of $3.70 billion, a P/E ratio of -20.28 and a beta of 0.02.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.37. NewAmsterdam Pharma had a negative return on equity of 27.27% and a negative net margin of 259.07%.The company had revenue of $19.15 million during the quarter, compared to the consensus estimate of $1.44 million. Analysts predict that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CAO Louise Frederika Kooij sold 150,000 shares of the business's stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $25.83, for a total transaction of $3,874,500.00. Following the completion of the transaction, the chief accounting officer owned 15,000 shares of the company's stock, valued at approximately $387,450. The trade was a 90.91% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Douglas F. Kling sold 51,043 shares of the business's stock in a transaction on Wednesday, July 16th. The stock was sold at an average price of $21.10, for a total value of $1,077,007.30. Following the transaction, the chief operating officer directly owned 44,000 shares of the company's stock, valued at $928,400. This trade represents a 53.71% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders purchased 2,391 shares of company stock worth $58,424 and sold 324,954 shares worth $7,844,906. Corporate insiders own 20.84% of the company's stock.

Institutional Investors Weigh In On NewAmsterdam Pharma

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. grew its position in NewAmsterdam Pharma by 2.4% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 22,549 shares of the company's stock worth $408,000 after acquiring an additional 521 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in NewAmsterdam Pharma by 5.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,868 shares of the company's stock worth $197,000 after acquiring an additional 544 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in NewAmsterdam Pharma by 19.4% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company's stock worth $80,000 after acquiring an additional 596 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. bought a new stake in NewAmsterdam Pharma during the 3rd quarter worth $30,000. Finally, Quarry LP bought a new stake in NewAmsterdam Pharma during the 1st quarter worth $25,000. Institutional investors own 89.89% of the company's stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.